BeOne Medicines (ONC) Common Equity (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Common Equity data on file, last reported at $4.8 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 36.03% year-over-year to $4.8 billion in Q1 2026; TTM through Mar 2026 was $4.8 billion, a 36.03% increase from a year earlier, with the FY2025 full-year figure at $4.4 billion, up 30.88% from the prior year.
• Common Equity for Q1 2026 stood at $4.8 billion, up from $4.4 billion in the prior quarter.
• Over the last five years, Common Equity for ONC reached as high as $5.8 billion in Q1 2022 and fell as low as $3.3 billion in Q4 2024.
• Historically, Common Equity has averaged $4.1 billion across 5 years, with a median of $3.8 billion in 2023.
• On a YoY basis, Common Equity climbed as much as 44.22% in 2022 and fell as far as 28.52% in 2022.
• Year by year, Common Equity stood at $4.4 billion in 2022, then slipped by 19.3% to $3.5 billion in 2023, then retreated by 5.8% to $3.3 billion in 2024, then soared by 30.88% to $4.4 billion in 2025, then increased by 9.15% to $4.8 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $4.8 billion in Q1 2026, $4.4 billion in Q4 2025, and $4.1 billion in Q3 2025.